Medtronic PLC (MDT)vsMaxCyte Inc (MXCT)
MDT
Medtronic PLC
$104.84
-2.90%
HEALTHCARE · Cap: $123.49B
MXCT
MaxCyte Inc
$1.26
-3.82%
HEALTHCARE · Cap: $135.20M
Smart Verdict
WallStSmart Research — data-driven comparison
Medtronic PLC generates 120804% more annual revenue ($37.54B vs $31.05M). MDT leads profitability with a 13.9% profit margin vs -114.8%. MDT earns a higher WallStSmart Score of 68/100 (B-).
MDT
Strong Buy68
out of 100
Grade: B-
MXCT
Avoid28
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-2.6%
Fair Value
$94.08
Current Price
$104.84
$10.76 premium
Intrinsic value data unavailable for MXCT.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Large-cap with strong market position
Reasonable price relative to book value
Earnings expanding 40.7% YoY
Generating 1.3B in free cash flow
Reasonable price relative to book value
Conservative balance sheet, low leverage
Areas to Watch
Expensive relative to growth rate
Grey zone — moderate risk
0.0% earnings growth
Distress zone — elevated risk
Smaller company, higher risk/reward
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : MDT
The strongest argument for MDT centers on Market Cap, Price/Book, EPS Growth. Revenue growth of 13.7% demonstrates continued momentum.
Bull Case : MXCT
The strongest argument for MXCT centers on Price/Book, Debt/Equity.
Bear Case : MDT
The primary concerns for MDT are PEG Ratio, Altman Z-Score.
Bear Case : MXCT
The primary concerns for MXCT are EPS Growth, Altman Z-Score, Market Cap.
Key Dynamics to Monitor
MDT profiles as a value stock while MXCT is a turnaround play — different risk/reward profiles.
MXCT carries more volatility with a beta of 1.48 — expect wider price swings.
MDT is growing revenue faster at 13.7% — sustainability is the question.
MDT generates stronger free cash flow (1.3B), providing more financial flexibility.
Bottom Line
MDT scores higher overall (68/100 vs 28/100) and 13.7% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Medtronic PLC
HEALTHCARE · MEDICAL DEVICES · USA
Medtronic plc is an American-Irish registered medical device company that primarily operates in the United States. Medtronic has an operational and executive headquarters in Fridley, Minnesota in the US.
MaxCyte Inc
HEALTHCARE · MEDICAL DEVICES · USA
MaxCyte Inc. (MXCT) is a leader in cell-engineering, renowned for its innovative Flow Electroporation® technology that enables efficient and scalable delivery of nucleic acids and proteins into a variety of cell types. The company serves a prestigious clientele, including top biopharmaceutical firms and research institutions, positioning it favorably within the rapidly expanding cell and gene therapy market. MaxCyte's advanced platforms play a crucial role in the development of novel cell-based therapies and vaccines, responding to the growing global demand for transformative healthcare solutions. With a steadfast commitment to enhancing patient outcomes, MaxCyte is poised to capitalize on significant market opportunities in the life sciences sector.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?